Vetr cut shares of Pfizer, Inc. (NYSE:PFE) from a buy rating to a hold rating in a research report report published on Wednesday morning. Vetr currently has $35.71 target price on the biopharmaceutical company’s stock.

A number of other research firms have also recently commented on PFE. Cowen and Company set a $43.00 price target on shares of Pfizer and gave the company a buy rating in a report on Monday, August 14th. Jefferies Group LLC set a $35.00 price target on shares of Pfizer and gave the company a neutral rating in a report on Thursday, August 24th. Berenberg Bank reiterated a hold rating and set a $36.00 price target (down previously from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. Zacks Investment Research upgraded shares of Pfizer from a sell rating to a hold rating in a report on Friday, July 14th. Finally, BidaskClub cut shares of Pfizer from a sell rating to a strong sell rating in a report on Thursday, July 13th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of Hold and an average price target of $37.72.

Pfizer (NYSE:PFE) opened at 35.36 on Wednesday. The company has a market cap of $210.30 billion, a PE ratio of 25.87 and a beta of 1.00. Pfizer has a 52-week low of $29.83 and a 52-week high of $35.84. The firm’s 50 day moving average is $33.64 and its 200 day moving average is $33.53.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the prior year, the company earned $0.64 earnings per share. The business’s revenue was down 1.9% compared to the same quarter last year. Analysts forecast that Pfizer will post $2.56 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/09/16/pfizer-inc-pfe-cut-to-hold-at-vetr-inc.html.

The business also recently announced a quarterly dividend, which was paid on Friday, September 1st. Investors of record on Friday, August 4th were paid a dividend of $0.32 per share. The ex-dividend date was Wednesday, August 2nd. This represents a $1.28 annualized dividend and a yield of 3.62%. Pfizer’s payout ratio is 94.12%.

In related news, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the transaction, the insider now directly owns 145,649 shares of the company’s stock, valued at $5,097,715. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. Insiders have sold 464,521 shares of company stock valued at $15,813,961 over the last ninety days. 0.06% of the stock is currently owned by corporate insiders.

Large investors have recently modified their holdings of the business. Asset Planning Services Ltd. grew its stake in shares of Pfizer by 4.9% in the 1st quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 137 shares in the last quarter. Shine Investment Advisory Services Inc. purchased a new position in shares of Pfizer in the 2nd quarter worth $102,000. Mckinley Capital Management LLC Delaware purchased a new position in shares of Pfizer in the 2nd quarter worth $103,000. D. Scott Neal Inc. grew its stake in shares of Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares in the last quarter. Finally, Orrstown Financial Services Inc. grew its stake in shares of Pfizer by 23.0% in the 1st quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares in the last quarter. 69.09% of the stock is owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.